检索结果-南通市图书馆

chinese Chemical Letters 2005年第11期16卷 1427-1430页

作者： ke he zheng hong zhou hong ying tang guo feng zhao chu chi tang State key Laboratory of Elemento-Organic Chemistry Institute of Elemento-Organic Chemistry Nankai University Tianjin 300071

chiral activated alkene, L-menthyl acrylate and （＋）-N-α-phenylethyl acrylamide, induced asymmetric Baylis-HiUman reaction of aromatic aldehydes was realized at 25℃ for 7 days in Me3N/H2O/solvent homogeneous medium. The corresponding Baylis-Hillman adducts were obtained in good chemical yield with moderate to excellent diastereoselectivity （up to 99% de）.

关键词： chiral activated alkene asymmetric Baylis-Hillman reaction aromatic aldehyde,diastereoselectivity

Nondestructive technique for identifying nuclides using neutron resonance transmission analysis at CSNS Back-n

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第1期35卷 178-187页

作者： Sheng-Da tang Yong-Hao Chen Jing-Yu tang Rui-Rui Fan Qiang Li Gong Li Dong Liu zheng-Yao Jin Xing-Zhu Cui Tian-Xiang Chen Yi-Wei Yang Rong Liu Han Yi Yang Li Zhen Yang Qi An Hao-Fan Bai Jiang-Bo Bai Jie Bao Ping Cao Qi-Ping Chen Zhen Chen Zeng-Qi Cui An-chuan Fan Chang-Qing feng Fan-Zhen feng ke-Qing Gao Min-Hao Gu Chang-Cai Han Zi-Jie Han guo-Zhu he Yong-Cheng he Yang hong Yi-Wei Hu Han-Xiong Huang Wei-Hua Jia Hao-yu Jiang Wei Jiang Zhi-jie Jiang Ling Kang Bo Li Chao Li Jia-Wen Li Xiao Li Jie Liu Shu-Bin Liu Guang-Yuan Luan Chang-Jun Ning Bin-Bin Qi Jie Ren Zhi-zhou Ren Xi-Chao Ruan zhao-Hui Song Kang Sun Zhi-Xin Tan Li-Jiao Wang Peng-Cheng Wang zhao-Hui Wang Zhong-Wei Wen Xiao-Guang Wu Xuan Wu Li-Kun Xie Yong-Ji Yu guo-Hui Zhang Lin-Hao Zhang Mo-Han Zhang Qi-Wei Zhang Xian-Peng Zhang Yu-Liang Zhang Yue Zhang Zhi-Yong Zhang Mao-Yuan zhao Lu-Ping zhou Zhi-Hao zhou ke-Jun Zhu Sino-French Institute of Nuclear Engineering and Technology Sun Yat-sen UniversityZhuhai 519082China Institute of High-Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China Spallation Neutron Source Science Center Dongguan 523803China School of Nuclear Science and Technology University of Science and Technology of ChinaHefei 230026China State key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China State key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China USTC Archaeometry Laboratory University of Science and Technology of ChinaHefei 230026China Institute of Nuclear Physics and Chemistry China Academy of Engineering PhysicsMianyang 621900China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China State key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China Northwest Institute of Nuclear Technology Xi’an 710024China University of chinese Academy of Sciences Beijing 100049China

Nondestructive and noninvasive neutron assays are essential applications of neutron *** resonance transmission analysis(NRTA)is a powerful nondestructive method for investigating the elemental composition of an *** back-streaming neutron line(Back-n)is a newly built time-of-flight facility at the china Spallation Neutron Source(CSNS)that provides neutrons in the eV to 300 MeV range.A feasibility study of the NRTA method for nuclide identification was conducted at the CSNS Back-n via two test *** results demonstrate that it is feasible to identify different elements and isotopes in samples using the NRTA method at *** study reveals its potential future applications.

关键词： CSNS White neutron beam NRTA Nuclide identification Nondestructive method

10B-doped MCP detector developed for neutron resonance imaging at Back-n white neutron source

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第8期35卷 58-68页

作者： Qiang Li Li‑Jiao Wang Jing‑Yu tang Xiang‑Biao Qiu Zhen Chen Mao‑Yuan zhao Chang‑Jun Ning Kai Pan Wei Xu Tao Li Su‑Peng Lu Han Yi Rui‑Rui Fan Chang‑Qing feng Rong Zhang Xiao‑Yang Sun Qi An Hao‑Fan Bai Jiang‑Bo Bai Jie Bao Ping Cao Qi‑Ping Chen Yong‑Hao Chen Zeng‑Qi Cui An‑chuan Fan Fan‑Zhen feng Min‑Hao Gu Chang‑Cai Han Zi‑Jie Han guo‑Zhu he Yong‑Cheng he Yang hong Yi‑Wei Hu Han‑Xiong Huang Wei Jiang Zhi‑Jie Jiang zheng‑Yao Jin Ling Kang Bo Li Gong Li Xiao Li Yang Li Jie Liu Rong Liu Shu‑Bin Liu Yi‑Na Liu Guang‑Yuan Luan Jie Ren Zhi‑zhou Ren Xi‑Chao Ruan zhao‑Hui Song Kang Sun Zhi‑Xin Tan Sheng‑Da tang Jin‑Cheng Wang Peng‑Cheng Wang zhao‑Hui Wang Zhong‑Wei Wen Xiao‑Guang Wu Xuan Wu Cong Xia Yong‑Ji Yu guo‑Hui Zhang Hang‑Chang Zhang Lin‑Hao Zhang Qi‑Wei Zhang Xian‑Peng Zhang Yu‑Liang Zhang Yue Zhang Zhi‑Yong Zhang Zhi‑Hao zhou ke‑Jun Zhu Chong Zou Institute of High Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China Spallation Neutron Source Science Center Dongguan 523803China State key Laboratory of Particle Detection and Electronics Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China Dongguan Songshan Lake Future School Dongguan 523808China School of Nuclear Science and Technology University of Science and Technology of ChinaHefei 230027China State key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China North Night Vision Science and Technology(Nanjing)Research Institute Co.Ltd Nanjing 211106China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China State key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China Institute of Modern Physics Fudan UniversityShanghai 200433China key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China china Academy of Engineering Physics Institute of Nuclear Physics and ChemistryMianyang 621900China USTC archaeometry lab University of Science and Technology of ChinaHefei 230026China Northwest Institute of Nuclear Technology Xi’an 710024China University of chinese Academy of Sciences Beijing 100049China china Shipbuilding Trading Co. LtdBeijing 100044China

Neutron resonance imaging(NRI)has recently emerged as an appealing technique for neutron *** complexity surpasses that of conventional transmission imaging,as it requires a high demand for both a neutron source and ***,the progression of NRI technology has been sluggish since its inception in the 1980s,particularly considering the limited studies analyzing the neutron energy range above *** white neutron source(Back-n)at the china Spallation Neutron Source(CSNS)provides favorable beam conditions for the development of the NRI technique over a wide neutron energy range from eV to ***-sensitive microchannel plates(MCP)have emerged as a cutting-edge tool in the field of neutron detection owing to their high temporal and spatial resolutions,high detection efficiency,and low *** this study,we report the development of a 10B-doped MCP detector,along with its associated electronics,data processing system,and NRI experiments at the *** heavy elements such as gold,silver,tungsten,and indium can be easily identified in the transmission images by their characteristic resonance peaks in the 1–100 eV energy range;the more difficult medium-weight elements such as iron,copper,and aluminum with resonance peaks in the 1–100 keV energy range can also be *** particular,results in the neutron energy range of dozens of keV(Aluminum)are reported here for the first time.

关键词： Neutron resonance imaging 10B doped MCP detector White neutron source Sample nuclide identification

Study of the response of 10B-doped MCP to wide-energy range neutrons from eV to MeV

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第8期35卷 132-141页

作者： Qiang Li Li‑Jiao Wang Xiang‑Biao Qiu Jing‑Wen Li Wei Xu Tao Li Ze‑Bin Lin Chang‑Jun Ning Yong‑Hao Chen Rui‑Rui Fan Kang Sun Jing‑Yu tang Rong Zhang Han‑Tao Jing Bo Mei Qi An Hao‑Fan Bai Jiang‑Bo Bai Jie Bao Ping Cao Qi‑Ping Chen Zhen Chen Zeng‑Qi Cui An‑chuan Fan Chang‑Qing feng Fan‑Zhen feng ke‑Qing Gao Min‑Hao Gu Chang‑Cai Han Zi‑Jie Han guo‑Zhu he Yong‑Cheng he Yang hong Yi‑Wei Hu Han‑Xiong Huang Wei‑Hua Jia Hao‑Yu Jiang Wei Jiang Zhi‑Jie Jiang zheng‑Yao Jin Ling Kang Bo Li Chao Li Gong Li Jia‑Wen Li Xiao Li Yang Li Jie Liu Rong Liu Shu‑Bin Liu Guang‑Yuan Luan Bin‑Bin Qi Jie Ren Zhi‑zhou Ren Xi‑Chao Ruan zhao‑Hui Song Zhi‑Xin Tan Sheng‑Da tang Peng‑Cheng Wang zhao‑Hui Wang Zhong‑Wei Wen Xiao‑Guang Wu Xuan Wu Li‑Kun Xie Yi‑Wei Yang Han Yi Yong‑Ji Yu guo‑Hui Zhang Lin‑Hao Zhang Mo‑Han Zhang Qi‑Wei Zhang Xian‑Peng Zhang Yu‑Liang Zhang Yue Zhang Zhi‑Yong Zhang Mao‑Yuan zhao Lu‑Ping zhou Zhi‑Hao zhou ke‑Jun Zhu Institute of High Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China Spallation Neutron Source Science Center Dongguan 523803China State key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China Dongguan Songshan Lake Future School Dongguan 523808China North Night Vision Science&Technology(Nanjing)Research Institute Co.Ltd. Nanjing 211106China Sino‑French Institute of Nuclear Engineering and Technology Sun Yat-sen UniversityZhuhai 519082China School of Nuclear Science and Technology University of Science and Technology of ChinaHefei 230027China State key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China State key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China Institute of Nuclear Physics and Chemistry China Academy of Engineering PhysicsMianyang 621900China key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China USTC Archaeometry Lab University of Science and Technology of ChinaHefei 230026China Northwest Institute of Nuclear Technology Xi’an 710024China University of chinese Academy of Sciences Beijing 100049China

Neutron-sensitive microchannel plates(nMCPs)have applications in neutron detection,including energy spectrum measurements,neutron-induced cross sections,and neutron imaging.10B-doped MCPs(B-MCPs)have attracted significant attention owing to their potential for exhibiting a high neutron detection efficiency over a large neutron energy *** spatial and temporal resolutions are useful for neutron energy-resolved ***,their practical applications still face many technical *** this study,a B-MCP with 10 mol%10B was tested for its response to wide-energy neutrons from eV to MeV at the Back-n white neutron source at the china Spallation Neutron *** neutron detection efficiency was calibrated at 1 eV,which is approximately 300 times that of an ordinary MCP and indicates the success of 10 B *** factors that caused the reduction in the detection efficiency were simulated and *** neutron energy spectrum obtained using B-MCP was compared with that obtained by other measurement methods,and showed very good consistency for neutron energies below tens of *** response is more complicated at higher neutron energy,at which point the elastic and nonelastic reactions of all nuclides of B-MCP gradually become *** is beneficial for the detection of neutrons,as it compensates for the detection efficiency of B-MCP for high-energy neutrons.

关键词： Neutron radiation image 10B-doped MCP Neutron response Wide-energy range neutrons

SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第1期7卷 295-309页

作者： Meng-Li Wu feng-Liang Liu Jing Sun Xin Li Xiao-Yan he hong-Yi zheng Yan-heng zhou Qihong Yan Ling Chen guo-ying Yu Junbiao Chang Xia Jin Jincun zhao Xin-Wen Chen Yong-tang zheng Jian-Hua Wang College of Life Science Henan Normal UniversityXinxiang 453007China key Laboratory of Animal Models and Human Disease Mechanisms of the chinese Academy of Sciences Kunming Institute of ZoologyChinese Academy of SciencesKunming 650223China State key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory DiseaseGuangzhou Institute of Respiratory HealthThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510182China Guangzhou Institutes of Biomedicine and health Chinese Academy of SciencesGuangzhou 510530China Bioland Laboratory Guangzhou Regenerative Medicine and Health Guangdong LaboratoryGuangzhou 510005China Shanghai Public health Clinical Center Affiliated to Fudan University Shanghai 201508China University of chinese Academy of Sciences Beijing 100039China

SARS-CoV-2 infection-induced hyper-inflammation links to the acute lung injury and COVID-19 *** the primary mediators that initiate the uncontrolled hypercytokinemia is essential for *** cells(MCs)are strategically located at the mucosa and beneficially or detrimentally regulate immune *** this study,we showed that SARS-CoV-2-triggered MC degranulation initiated alveolar epithelial inflammation and lung ***-CoV-2 challenge induced MC degranulation in ACE-2 humanized mice and rhesus macaques,and a rapid MC degranulation could be recapitulated with Spike-RBD binding to ACE2 in cells;MC degranulation altered various signaling pathways in alveolar epithelial cells,particularly,the induction of pro-inflammatory factors and consequential disruption of tight ***,the administration of clinical MC stabilizers for blocking degranulation dampened SARS-CoV-2-induced production of pro-inflammatory factors and prevented lung *** findings uncover a novel mechanism for SARS-CoV-2 initiating lung inflammation,and suggest an off-label use of MC stabilizer as immunomodulators for COVID-19 treatments.

关键词： inflammation lung alveolar

CEPC Technical Design Report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen chunhui Chen Hok chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong chi Pietro chimenti Wen Han chiu Guk Cho Ming-chung chu Xiaotong chu Ziliang chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced Science and Technology Beijing china Institute of Atomic Energy Beijing china Jiliang University HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china University of Geosciences Beijing china University of Geosciences WuhanHubei china University of Mining and Technology XuzhouJiangsu china West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing chulalongkorn University Bangkok City University of hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East china University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

基于白光中子源的^(197)Au中子辐射俘获截面测量及共振参数分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

物理学报 2024年第7期73卷 104-113页

作者：罗淏天张奇玮栾广源王晓宇邹翀任杰阮锡超贺国珠鲍杰孙琪黄翰雄王朝辉吴鸿毅顾旻皓余滔解立坤陈永浩安琪白怀勇鲍煜曹平陈昊磊陈琪萍陈裕凯陈朕崔增琪樊瑞睿封常青高可庆韩长材韩子杰何泳成洪杨黄蔚玲黄锡汝季筱璐吉旭阳蒋伟江浩雨姜智杰敬罕涛康玲康明涛李波李超李嘉雯李论李强李晓李样刘荣刘树彬刘星言穆奇丽宁常军齐斌斌任智洲宋英鹏宋朝晖孙虹孙康孙晓阳孙志嘉谭志新唐洪庆唐靖宇唐新懿田斌斌王丽娇王鹏程王琦王涛峰文杰温中伟吴青彪吴晓光吴煊羊奕伟易晗于莉于永积张国辉张林浩张显鹏张玉亮张志永赵豫斌周路平周祖英朱丹阳朱科军朱鹏朱兴华中国原子能科学研究院核数据重点实验室北京102413 中国科学院高能物理研究所北京100049 散裂中子源科学中心东莞523803 核探测与核电子学国家重点实验室北京100049 中国科学技术大学近代物理系核探测与核电子学国家重点实验室合肥230026 北京大学物理学院核物理与核技术国家重点实验室北京100871 中国工程物理研究院核物理与化学研究所绵阳621900 西北核技术研究院西安710024 中国科学院大学北京100049 中国科学技术大学工程与应用物理系合肥230026 北京航空航天大学物理学院北京100083 华能山东石岛湾核电有限公司荣成264312

中子辐射俘获反应在反应堆运行、核装置设计及核天体物理研究中起重要的作用.4πBaF_(2)探测装置有着高时间分辨能力、低中子灵敏度、高探测效率等优点,适合开展中子辐射俘获反应截面数据的测量.中国原子能科学研究院核数据重点实验室... 详细信息

中子辐射俘获反应在反应堆运行、核装置设计及核天体物理研究中起重要的作用.4πBaF_(2)探测装置有着高时间分辨能力、低中子灵敏度、高探测效率等优点,适合开展中子辐射俘获反应截面数据的测量.中国原子能科学研究院核数据重点实验室建立了伽马全吸收装置(Gamma total absorption facility,GTAF),该装置用28块六棱BaF_(2)晶体和12块五棱BaF_(2)晶体构成了外径25 cm,内径10 cm的球壳,覆盖了95.2%的立体角.利用GTAF在中国散裂中子源Back-n束线上,测量了197Au(n,γ)的反应截面数据.测量数据通过能量筛选、PSD方法、晶体多重性筛选进行了初步本底扣除,随后结合对^(nat)C及空样品的测量数据对本底进行了分析及扣除,获得了197Au俘获反应的产额,利用SAMMY程序拟合得到了^(197)Au在1—100 e V的共振能量、中子共振宽度和伽马共振宽度参数.实验测量结果与ENDF/B-VIII.0数据库符合良好,其共振参数存在一定差异,分析原因可能与GTAF能量分辨率、Back-n的中子能谱测量精度、以及实验本底扣除方法相关,这也是下一步工作的重点.

关键词：中子辐射俘获截面共振参数白光中子源伽马全吸收装置

维普期刊数据库博看期刊

GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson's disease:a two-cohort case-control study

在线全文

学校读者我要写书评

暂无评论

Translational Neurodegeneration 2020年第3期9卷 409-420页

作者： hong-xu Pan Yu-wen zhao Jun-pu Mei zheng-huan Fang Yige Wang Xun zhou Yang-jie zhou Rui Zhang Kai-lin Zhang Li Jiang Qian Zeng Yan he zheng Wang Zhen-hua Liu Qian Xu Qi-ying Sun Yang Yang Ya-cen Hu Ya-se Chen Juan Du Li-fang Lei Hai-nan Zhang chun-yu Wang Xin-xiang Yan Lu Shen hong Jiang Jie-qiong Tan Jin-chen Li Bei-sha tang Ji-feng guo Department of Neurology Xiangya HospitalCentral South UniversityChangsha 410008China National Clinical Research Center for Geriatric Disorders Xiangya HospitalCentral South UniversityChangsha 410008China Centre for Medical Genetics and Hunan key Laboratory of Medical Genetics School of Life SciencesCentral South UniversityChangsha 410008China Department of Geriatrics Xiangya HospitalCentral South UniversityChangsha 410008China Department of Neurology The Third Xiangya HospitalCentral South UniversityChangsha 410013China Department of Neurology The Second Xiangya HospitalCentral South UniversityChangsha 410011China key Laboratory of Hunan Province in Neurodegenerative Disorders Central South UniversityChangsha 410008China

Background:Common and rare variants of guanosine triphosphate cyclohydrolase 1(GCH1)gene may play important roles in Parkinson's disease(PD).However,there is a lack of comprehensive analysis of GCH1 genotypes,especially in non-coding *** aim of this study was to explore the genetic characteristics of GCH1,including rare and common variants in coding and non-coding regions,in a large population of PD patients in chinese mainland,as well as the phenotypic characteristics of GCH1 variant ***:In the first cohort of this case-control study,we performed whole-exome sequencing in 1555 patients with early-onset or familial PD and 2234 healthy controls;then in the second cohort,whole-genome sequencing was performed in sporadic late-onset PD samples(1962 patients),as well as 1279 *** at target GCH1 regions were extracted,and then genetic and detailed phenotypic data were analyzed using regression models and the sequence kernel association *** also performed a meta-analysis to correlate deleterious GCH1 variants with age at onset(AAO)in PD ***:For coding variants,we identified a significant burden of GCH1 deleterious variants in early-onset or familial PD cases compared to controls(1.2%VS 0.1%,Phe analysis of possible regulatory variants in GCH1 non-coding regions,rs12323905(P=0.001,odds ratio=1.19,95%CI 1.07-1.32)was significantly associated with PD,and variant sets in untranslated regions and intron regions,GCH1 brain-specific expression quantitative trait loci,and two possible promoter/enhancer(GH14J054857 and GH14J054880)were suggestively associated with *** phenotype correlation analysis revealed that the carriers of GCH1 deleterious variants manifested younger AAO(Phe results

关键词： Parkinson's disease Age at onset GCH1 Deleterious variants Non-coding variants

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第6期6卷 1845-1855页

作者： Huijie Bian zhao-Hui zheng Ding Wei Aidong Wen zheng Zhang Jian-Qi Lian Wen-Zhen Kang chun-Qiu Hao Jing Wang Rong-Hua Xie ke Dong Jie-Lai Xia Jin-Lin Miao Wen Kang guoquan Li Di Zhang Mingru Zhang Xiu-Xuan Sun Likun Ding Kui Zhang Junfeng Jia Jin Ding Zhiqin Li Yanyan Jia Lin-Na Liu Zhe Zhang zhao-Wei Gao hong Du Na Yao Qing Wang ke Wang Jie-Jie Geng Bin Wang Ting guo Ruo Chen Yu-Meng Zhu Li-Juan Wang Qian he Rui-Rui Yao ying Shi Xiang-Min Yang Jian-Sheng zhou Yi-Nan Ma Ya-Tao Wang Xue Liang Fei Huo Zhe Wang Yang Zhang Xu Yang Ye Zhang Lu-Hua Gao Ling Wang Xiao-chun Chen Hao tang Shuang-Shuang Liu Qing-Yi Wang Zhi-Nan Chen Ping Zhu National Translational Science Center for Molecular Medicine and Department of Cell Biology Fourth Military Medical UniversityXi'anChina Department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi'anChina Department of Pharmacy Xijing HospitalFourth Military Medical UniversityXi'anChina Center for Infectious Diseases Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Nuclear Medicine Xijing HospitalFourth Military Medical UniversityXi'anChina department of Clinical Diagnosis Tangdu HospitalFourth Military Medical UniversityXKanChina College of Military Preventive Medicine Fourth Military Medical UniversityXi'anChina Department of Pharmaceutics Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Pathology Fourth Military Medical UniversityXi'anChina Jiangsu Pacific Meinuoke Biopharmaceutical Co.Ltd ChangzhouChina Department of Foreign Languages Fourth Military Medical UniversityXi'anChina

Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)*** CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 *** is a humanized anti-CD147 IgG_(2) monoclonal antibody,which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019(COVID-19)***,we conducted a randomized,double-blinded,placebo-controlled phase 1 trial to evaluate the safety,tolerability,and pharmacokinetics of meplazumab in healthy subjects,and an open-labeled,concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 *** phase 1 study,59 subjects were enrolled and assigned to eight cohorts,and no serious treatment-emergent adverse event(TEAE)or TEAE grade≥3 was *** serum and peripheral blood Cmax and area under the curve showed non-linear pharmacokinetic *** obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each *** biodistribution study indicated that meplazumab reached lung tissue and maintained>14 days stable with the lung tissue/cardiac blood-pool ratio ranging from 0.41 to *** the exploratory phase 2 study,17 COVID-19 patients were enrolled,and 11 hospitalized patients were involved as concurrent *** meplazumab treatment significantly improved the discharged(P=0.005)and case severity(P=0.021),and reduced the time to virus negative(P=0.045)in comparison to the control *** results show a sound safety and tolerance of meplazumab in healthy volunteers and suggest that meplazumab could accelerate the recovery of patients from COVID-19 pneumonia with a favorable safety profile.

关键词： patients dosage phase

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong he Minghong Bi Xicheng Wang Jianhua Shi Ming zhou Qian Sun guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang guo Yong Liu Junquan Yang ke Wang ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu yinghua Ji guolong Liu hong Lu Dedong Wu Junhong Zhang Shuyang Zhu zheng Liu Wensheng Qiu feng Ye Yan Yu Yanqiu zhao Qinhong zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu guojun Zhang Hua Zhang Yanju Chen Yuan Chen hongbing Duan Manxiang Li Shengming Liu Lijun Ma hongming Pan Xia Yuan Xueli Yuan Yulong zheng Emei Gao Li zhao Shumin Wang Can Wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across china were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor